The Activity of Prebiotics and Probiotics in Hepatogastrointestinal Disorders and Diseases Associated with Metabolic Syndrome

Int J Mol Sci. 2022 Jun 29;23(13):7229. doi: 10.3390/ijms23137229.

Abstract

The components of metabolic syndrome (MetS) and hepatogastrointestinal diseases are widespread worldwide, since many factors associated with lifestyle and diet influence their development and correlation. Due to these growing health problems, it is necessary to search for effective alternatives for prevention or adjuvants in treating them. The positive impact of regulated microbiota on health is known; however, states of dysbiosis are closely related to the development of the conditions mentioned above. Therefore, the role of prebiotics, probiotics, or symbiotic complexes has been extensively evaluated; the results are favorable, showing that they play a crucial role in the regulation of the immune system, the metabolism of carbohydrates and lipids, and the biotransformation of bile acids, as well as the modulation of their central receptors FXR and TGR-5, which also have essential immunomodulatory and metabolic activities. It has also been observed that they can benefit the host by displacing pathogenic species, improving the dysbiosis state in MetS. Current studies have reported that paraprobiotics (dead or inactive probiotics) or postbiotics (metabolites generated by active probiotics) also benefit hepatogastrointestinal health.

Keywords: gut microbiota; immunomodulation; lipids; liver; metabolic syndrome; prebiotics; probiotics.

Publication types

  • Review

MeSH terms

  • Dysbiosis / complications
  • Dysbiosis / therapy
  • Gastrointestinal Microbiome*
  • Humans
  • Metabolic Syndrome* / complications
  • Metabolic Syndrome* / therapy
  • Prebiotics
  • Probiotics* / therapeutic use

Substances

  • Prebiotics

Grants and funding

This research received no external funding.